Management Team

amelia Amelia Wall Warner
Founder and CEO

Dr. Amelia Warner founded Global Specimen Solutions, Inc. in 2013 with the vision of radically improving translational science through powerful new pipeline data management analytics. Prior to GSS, Amelia served as CEO, President and Director of the Board for Gentris Corporation, where she led a financial and operational turnaround resulting in the successful sale of Gentris to a public company.Amelia served as the Head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL). She oversaw all clinical pharmacogenomics projects, as well as policies and procedures for biosample collection and storage for clinical trial samples; she also served as the MRL Pharmacogenomics Expert for the Translational Science Research Network. She was the MRL Key Expert for Global Regulation for Genetic Research and Human Specimen Usage Regulation/Law. She served as Chair of the Industry Pharmacogenomics Working Group (I-PWG) and a PhRMA Representative to ICH E16- Genomic Biomarkers Related to Drug Response.

Amelia completed a Residency in Pediatric Pharmacotherapy at St. Jude Children’s Research Hospital and a Fellowship in Clinical Pharmacology/Pharmacogenomics at St. Jude Children’s Research Hospital with William Evans, PharmD. Amelia holds a BS in Biology from Wake Forest University and a PharmD from the University of North Carolina at Chapel Hill.

Tom Wollman
COO/CFO Operations and Finance

Tom brings more than 30 years of financial and operational experience to GSS, with a track record of driving profitable revenue growth through organic and acquisition-based expansion. Tom served as Senior Vice President of Quintiles Clinical Operations and SVP of Quintiles Central Labs delivering strategic leadership to global clinical operations businesses. Quintiles’ global laboratory business grew from ~$50M to ~$400M during Tom’s tenure and included roughly 1,900 employees and laboratories in the US, Europe, Asia, Latin America and Africa. Prior to SVP roles, Tom served as CFO for Quintiles Laboratories and for two publicly traded companies. Tom received his BA in Economics from Dickinson College and his MBA in accounting from Rutgers.

Pete Tearle
Chief Technology Officer

Pete brings GSS more than 30 years of business solution engineering expertise across all major application facets – vendor, employee and customer. Pete has provided strategic analysis and leadership from implementation through service assurance delivering fully integrated business solutions in healthcare and manufacturing sectors. Before joining GSS, Pete spent two years at Medfusion as VP of IT, developing and delivering an IT strategy to meet the organization’s desire to be a molecular center of excellence. Prior to Medfusion, Pete worked for approximately 10 years in various technical and managerial roles at Quintiles, from enterprise architect to business line product manager. Before Quintiles, Pete’s career included an entrepreneurial stint and roles at GE Healthcare and MDS. Pete holds a BSc in Software Engineering from University College of Wales, Aberystwyth, and he completed the Executive Program from Queen’s University School of Business in Kingston, Ontario.

L. Scott Clark
VP, Global Quality Assurance

L. Scott Clark received his Ph.D. in Cell and Molecular Biology from the University of Vermont.  After his post-doctoral fellowship with the University of North Carolina-Chapel Hill and the EPA, Scott started his career in regulated research and clinical contract work.  Scott had over 18 years of experience in genetic toxicology, pharmacogenomics and genetics.  He has held several executive roles including Research and Development, Clinical Operations, Scientific Affairs, and Global Quality Assurance.  Dr. Clark also is an Adjunct Assistant Professor at UNCCH in the Division of Pharmacotherapy and Experimental Therapeutics.  Scott is now bringing his quality assurance, scientific, and business experience to Global Specimen Solutions to enable clients to maximize their specimens for current and future biomedical research.